Galderma has received EU regulatory approval to market Restylane Shaype for chin augmentation, adding a lower-face indication to the hyaluronic acid injector's label in Europe.

The green light from European authorities covers the use of Restylane Shaype specifically for chin augmentation, a treatment area that has historically relied on either off-label use of existing fillers, autologous fat transfer or permanent implants. The move gives Galderma an on-label position in a segment where demand has grown alongside the broader boom in non-surgical facial balancing procedures.

What does the approval change for clinics?

Practitioners across the EU can now offer chin augmentation using Restylane Shaype with the backing of an approved indication rather than relying on off-label protocols. That shift has practical consequences beyond marketing:

• Clearer patient consent documentation
• Defined treatment protocols supported by Galderma training
• Eligibility for standard adverse-event reporting pathways tied to the approved use
• Reduced regulatory exposure compared with off-label lower-face work

For clinic operators, the addition of an on-label chin product from the Restylane range also creates a procurement pathway: existing Restylane accounts can add a new indication to a familiar supplier relationship rather than sourcing a separate device.

Where does Shaype sit in the Restylane line-up?

Restylane Shaype is part of Galderma's hyaluronic acid injectable portfolio, joining established products such as Restylane, Restylane Lyft, Restylane Kysse and Restylane Volyme. The Shaype product is engineered for shaping and projection work, a category that includes cheek augmentation, jawline contouring and now chin enhancement. Its addition to the EU label reflects the manufacturer's strategy to position a dedicated shaping device across the mid and lower face.

How does this fit the EU filler market?

Chin augmentation sits inside the wider non-surgical lower-face contouring segment, which has expanded steadily in Europe as patients seek alternatives to surgical genioplasty. Competitor hyaluronic acid fillers and biostimulators have addressed parts of this demand, but on-label chin options remain comparatively limited. The Restylane Shaype approval narrows that gap and gives Galderma direct competition with devices from AbbVie (Allergan Aesthetics), Merz and Teoxane in the shaping category.

What practitioners should expect next

Galderma has not yet detailed the country-level launch schedule or training rollout in Europe, but the company typically follows an EU CE-style approval with phased national availability and structured injector training. Clinics should expect:

• Product availability through existing Galderma distribution partners in major EU markets first
• Mandatory or strongly recommended practitioner training before first use
• Marketing materials positioning Shaype within a defined treatment protocol rather than as a standalone filler

The next data points to watch are the country-by-country commercial launch dates and any post-market clinical data Galderma publishes for the chin indication. Pricing for the new indication has not been disclosed; clinics planning to add the treatment should expect price parity or a modest premium relative to existing Restylane Shaype use cases.